{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:22:04Z","timestamp":1784661724428,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07719-9","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T16:34:51Z","timestamp":1771086891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The immunological fitness of NSCLC patients drives the response to anti-PD1-based immunotherapy regardless of age"],"prefix":"10.1186","volume":"24","author":[{"given":"Lucrezia","family":"Tuosto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gelibter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Strigari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Asquino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Siringo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Bellati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Nuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria Grazia","family":"Zizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"Rughetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5449-5430","authenticated-orcid":false,"given":"Chiara","family":"Napoletano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"1","key":"7719_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"7719_CR2","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623\u201340.","journal-title":"Mayo Clin Proc"},{"issue":"19","key":"7719_CR3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"21","key":"7719_CR4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040\u201351.","journal-title":"N Engl J Med"},{"issue":"2","key":"7719_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198\u2013211.","journal-title":"Lancet Oncol"},{"issue":"6","key":"7719_CR6","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C Lopez-Otin","year":"2013","unstructured":"Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194\u2013217.","journal-title":"Cell"},{"issue":"4","key":"7719_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s10522-017-9682-z","volume":"18","author":"G Pawelec","year":"2017","unstructured":"Pawelec G. Immunosenescence and cancer. Biogerontology. 2017;18(4):717\u201321.","journal-title":"Biogerontology"},{"issue":"1","key":"7719_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","volume":"8","author":"Z Liu","year":"2023","unstructured":"Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther. 2023;8(1):200.","journal-title":"Signal Transduct Target Ther"},{"key":"7719_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.exger.2017.10.002","volume":"107","author":"V Hurez","year":"2018","unstructured":"Hurez V, Padron A, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Exp Gerontol. 2018;107:27\u201336.","journal-title":"Exp Gerontol"},{"issue":"2","key":"7719_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/acel.12435","volume":"15","author":"KA Lee","year":"2016","unstructured":"Lee KA, Shin KS, Kim GY, Song YC, Bae EA, Kim IK, et al. Characterization of age-associated exhausted CD8(+) T cells defined by increased expression of Tim-3 and PD-1. Aging Cell. 2016;15(2):291\u2013300.","journal-title":"Aging Cell"},{"issue":"10","key":"7719_CR11","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.febslet.2005.02.055","volume":"579","author":"M De Martinis","year":"2005","unstructured":"De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005;579(10):2035\u201339.","journal-title":"FEBS Lett"},{"key":"7719_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fimmu.2018.00586","volume":"9","author":"IM Rea","year":"2018","unstructured":"Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9:586.","journal-title":"Front Immunol"},{"issue":"21","key":"7719_CR13","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","volume":"24","author":"CH Kugel 3rd","year":"2018","unstructured":"Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, et al. Age correlates with response to anti-PD1, reflecting age-related differences in Intratumoral effector and regulatory T-Cell populations. Clin Cancer Res. 2018;24(21):5347\u201356.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"7719_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/acel.12191","volume":"13","author":"SK Garg","year":"2014","unstructured":"Garg SK, Delaney C, Toubai T, Ghosh A, Reddy P, Banerjee R, et al. Aging is associated with increased regulatory T-cell function. Aging Cell. 2014;13(3):441\u201348.","journal-title":"Aging Cell"},{"issue":"5","key":"7719_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10522-018-9762-8","volume":"19","author":"A Salminen","year":"2018","unstructured":"Salminen A, Kauppinen A, Kaarniranta K. Myeloid-derived suppressor cells (MDSC): an important partner in cellular\/tissue senescence. Biogerontology. 2018;19(5):325\u201339.","journal-title":"Biogerontology"},{"issue":"1","key":"7719_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.immuni.2019.12.018","volume":"52","author":"J Galon","year":"2020","unstructured":"Galon J, Bruni D. Tumor Immunology and tumor evolution: intertwined histories. Immunity. 2020;52(1):55\u201381.","journal-title":"Immunity"},{"key":"7719_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1749-6632.2009.05370.x","volume":"1197","author":"T Fulop","year":"2010","unstructured":"Fulop T, Kotb R, Fortin CF, Pawelec G, de Angelis F, Larbi A. Potential role of immunosenescence in cancer development. Ann N Y Acad Sci. 2010;1197:158\u201365.","journal-title":"Ann N Y Acad Sci"},{"key":"7719_CR18","doi-asserted-by":"crossref","unstructured":"Berben L, Floris G, Wildiers H, Hatse S. Cancer and aging: two tightly interconnected biological processes. Cancers (Basel). 2021;13(6).","DOI":"10.3390\/cancers13061400"},{"key":"7719_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/978-3-030-38862-1_9","volume":"180","author":"JA Chen","year":"2020","unstructured":"Chen JA, Ma W, Yuan J, Li T. Translational biomarkers and rationale strategies to overcome resistance to immune checkpoint inhibitors in solid tumors. Cancer Treat Res. 2020;180:251\u201379.","journal-title":"Cancer Treat Res"},{"key":"7719_CR20","unstructured":"Cancer stat facts: lung and bronchus cancer. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html."},{"issue":"3","key":"7719_CR21","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1172\/JCI64096","volume":"123","author":"E Montecino-Rodriguez","year":"2013","unstructured":"Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013;123(3):958\u201365.","journal-title":"J Clin Invest"},{"issue":"3","key":"7719_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.mad.2005.11.001","volume":"127","author":"P Saule","year":"2006","unstructured":"Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev. 2006;127(3):274\u201381.","journal-title":"Mech Ageing Dev"},{"issue":"4","key":"7719_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1189\/jlb.0912461","volume":"93","author":"CP Verschoor","year":"2013","unstructured":"Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M, Lelic A, et al. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol. 2013;93(4):633\u201337.","journal-title":"J Leukoc Biol"},{"key":"7719_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arr.2018.09.001","volume":"48","author":"A Salminen","year":"2018","unstructured":"Salminen A, Kaarniranta K, Kauppinen A. The role of myeloid-derived suppressor cells (MDSC) in the inflammaging process. Ageing Res Rev. 2018;48:1\u201310.","journal-title":"Ageing Res Rev"},{"issue":"12","key":"7719_CR25","doi-asserted-by":"publisher","first-page":"8348","DOI":"10.4049\/jimmunol.177.12.8348","volume":"177","author":"S Sharma","year":"2006","unstructured":"Sharma S, Dominguez AL, Lustgarten J. High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol. 2006;177(12):8348\u201355.","journal-title":"J Immunol"},{"issue":"1","key":"7719_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","volume":"20","author":"Q Ye","year":"2014","unstructured":"Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res. 2014;20(1):44\u201355.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7719_CR27","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1158\/1078-0432.CCR-21-2918","volume":"28","author":"IG Zizzari","year":"2022","unstructured":"Zizzari IG, Di Filippo A, Botticelli A, Strigari L, Pernazza A, Rullo E, et al. Circulating CD137+ T cells correlate with improved response to anti-PD1 immunotherapy in patients with cancer. Clin Cancer Res. 2022;28(5):1027\u201337.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"7719_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.62347\/NCYZ7977","volume":"18","author":"M Leopizzi","year":"2025","unstructured":"Leopizzi M, Pernazza A, Rullo E, Cerbelli B, Pisano A, Anile M, et al. Evaluation of immune microenvironment in non-small cell lung carcinoma after neoadjuvant immunotherapy: a case report. Int J Clin Exp Pathol. 2025;18(7):405\u201313.","journal-title":"Int J Clin Exp Pathol"},{"key":"7719_CR29","doi-asserted-by":"publisher","first-page":"107925","DOI":"10.1016\/j.lungcan.2024.107925","volume":"195","author":"Y Ding","year":"2024","unstructured":"Ding Y, Lei S, Wang L, Tang L, Zhang Y, Liao Y, et al. Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a comprehensive meta-analysis. Lung Cancer. 2024;195:107925.","journal-title":"Lung Cancer"},{"issue":"1","key":"7719_CR30","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1038\/s41467-025-58512-z","volume":"16","author":"C Kao","year":"2025","unstructured":"Kao C, Charmsaz S, Tsai HL, Aziz K, Shu DH, Munjal K, et al. Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors. Nat Commun. 2025;16(1):3531.","journal-title":"Nat Commun"},{"issue":"3","key":"7719_CR31","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.4049\/jimmunol.181.3.1835","volume":"181","author":"CS Lages","year":"2008","unstructured":"Lages CS, Suffia I, Velilla PA, Huang B, Warshaw G, Hildeman DA, et al. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol. 2008;181(3):1835\u201348.","journal-title":"J Immunol"},{"issue":"2","key":"7719_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1164\/rccm.201808-1502LE","volume":"199","author":"HR Kim","year":"2019","unstructured":"Kim HR, Park SM, Seo SU, Jung I, Yoon HI, Gabrilovich DI, et al. The ratio of peripheral regulatory T cells to lox-1(+) polymorphonuclear myeloid-derived suppressor cells predicts the early response to anti-PD-1 therapy in patients with non-small cell lung cancer. Am J Respir Crit Care Med. 2019;199(2):243\u201346.","journal-title":"Am J Respir Crit Care Med"},{"key":"7719_CR33","doi-asserted-by":"crossref","unstructured":"Han J, Khatwani N, Searles TG, Turk MJ, Angeles CV. Memory CD8(+) T cell responses to cancer. Semin Immunol. 2020;49:101435.","DOI":"10.1016\/j.smim.2020.101435"},{"key":"7719_CR34","doi-asserted-by":"crossref","unstructured":"Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24(7):994\u20131004","DOI":"10.1038\/s41591-018-0057-z"},{"key":"7719_CR35","doi-asserted-by":"crossref","unstructured":"Lee DH, Kim M, Kim M, Lee YJ, Yoo HJ, Lee SH, et al. Age-dependent alterations in serum cytokines, peripheral blood mononuclear cell cytokine production, natural killer cell activity, and prostaglandin F(2alpha). Immunol Res. 2017;65(5):1009\u201316.","DOI":"10.1007\/s12026-017-8940-0"},{"key":"7719_CR36","doi-asserted-by":"crossref","unstructured":"Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120(1):16\u201325.","DOI":"10.1038\/s41416-018-0333-1"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07719-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07719-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07719-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:42:29Z","timestamp":1774280549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07719-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7719"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07719-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Policlinico Umberto I (Ethical Committee Protocol, RIF.CE: 4181). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors provided their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests regarding this work. MS reports travel grants from Novartis and speaker\u2019s honoraria. AG received speaker\u2019s honoraria.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"397"}}